Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).
2025 · 1st Quarter (Jan 1 - Mar 31)
NOVARTIS
Filed by TIBER CREEK HEALTH STRATEGIES, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 17, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK HEALTH STRATEGIES, INC.
- Client
- NOVARTIS
- Filing UUID
- f4c32bad-6ed6-492a-b453-d7de90213ea9
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to PBM reform.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.